Preclinical Oncology Services Limited (PRECOS), the oncology-focused research and development provider spun out from the University of Nottingham in the UK, has launched a suite of premium bespoke lung-oncology models for in vitro and in vivo drug-discovery screening.

The Lung In ONcology model atlas (LION) is part of the PRECOS PREdict platform for target discovery, offering “unique” panels of patient-derived in vitro and in vivo research models that are characterised, validated and ready to run.

The new models are aimed at pharmaceutical and biopharmaceutical companies looking to deliver significantly higher research productivity for their portfolio of therapeutic targets, PRECOS said.

The LION technology uses a pharmacological audit trail (PhAT) to construct a rational framework for assessing the risk profile of new agents, so that predictive lung models can be matched to each stage of the decision-making process, the company noted.

Novel compounds identified by a proprietary 3D tumour-growth assay (TGA) are assessed against multiple standards of care and in combination therapies to develop a ‘map’ of lead therapeutics against the landscape of existing treatments, PRECOS explained.